Brookhaven Lab Receives $28 Million to Support Crystallography Facility
The U.S. Department of Energys (DOE) Brookhaven National Laboratory received grants from DOE and the National Institutes of Health (NIH) totaling $28 million to support an X-ray Crystallography Research Resource at the Laboratorys National Synchrotron Light Source (NSLS).
Lab Manager provides guidance and resources to help laboratory leaders run their labs like a business. We are the only publication specifically focused on all aspects of running a lab.
One of the world’s most widely used scientific facilities, the NSLS provides intense beams of infrared, ultraviolet, and x-ray light to study materials as diverse as computer chips and viruses at the atomic level. X-ray crystallography at the NSLS involves experiments that reveal the 3-D atomic-level structure of large molecules, such as enzymes and nucleic acids that are found in all living cells. X-ray crystallographers working at the NSLS determined the structures of numerous molecules, including those from organisms responsible for the common cold, Lyme disease, and AIDS. Knowing the structure of a molecule provides information about its function, which, in turn, may lead to important clues about how to create effective drugs to prevent or treat a disease.
“During the last year, 150 university, industrial and national laboratory research groups made a total of 800 visits to work at this resource,” said Brookhaven’s Robert Sweet, the principal investigator of the X-ray Crystallography Research Resource, which has a staff of 20. “Their experimental results provide crucial information that may lead to treatments for many health problems, including cancer, infections, and obesity.”
One of the guest investigators who did research at the crystallography resource – Roderick MacKinnon of Rockefeller University – won the 2003 Nobel Prize in Chemistry for investigating the molecular details of nerve transmission. While much of the research at the facility is basic science that may lead to major discoveries, other work is targeted toward achieving a specific, practical goal. For example, about five percent of the research is done by pharmaceutical firms with the goal of finding drugs to treat human disease.
